Treating cancers with combinations of parp inhibitor and acylfulvenes

EP4376822A4Pending Publication Date: 2025-09-17LANTERN PHARMA INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
EP2022850545
Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-06-07
Filing Date
2022-07-29
Publication Date
2025-09-17

AI Technical Summary

Technical Problem

Current cancer treatments face challenges with resistance to anticancer agents, leading to poor prognosis for advanced cancer patients, necessitating the development of effective combination therapies that target multiple mechanisms of cancer drug resistance.

Method used

A combination therapy using a PARP inhibitor and an illudin or acylfulvene, which synergistically enhances cytotoxicity and tumor shrinkage, allowing for lower therapeutic doses and reduced toxicity, effectively targeting various types of cancers including solid tumors and hematological malignancies.

Benefits of technology

The combination therapy demonstrates greater cytotoxicity and faster tumor shrinkage compared to monotherapies, achieving synergistic effects that are not attainable with either agent alone, thereby improving treatment outcomes for cancer patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 1.1
    Figure 1.1
Patent Text Reader

Abstract

A method of treating cancer includes a combination of a therapeutically effective amount of an illudin or an illudin analog thereof, derivative, or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of a PARP inhibitor or an analog, derivative, or a pharmaceutically acceptable salt thereof. Compositions and kits of the same are included herein.
Need to check novelty before this filing date? Find Prior Art